We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Citius Pharmaceuticals, Inc. is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: Mino-Lok, which is an antibiotic lock solution used to treat patient... Citius Pharmaceuticals, Inc. is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome. Show more
Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution PR Newswire CRANFORD, N.J., May 21, 2024 Trial achieves statistically...
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update PR Newswire CRANFORD, N.J., May 14, 2024 Mino-Lok data analysis on track with...
Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences PR Newswire CRANFORD, N.J., May 10, 2024 CRANFORD, N.J., May 10, 2024 /PRNewswire/ -- Citius...
Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering PR Newswire CRANFORD, N.J., April 30, 2024 CRANFORD, N.J., April 30, 2024 /PRNewswire/ -- Citius Pharmaceuticals...
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering PR Newswire CRANFORD, N.J., April 26, 2024 CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc...
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma PR Newswire CRANFORD, N.J., April 11...
Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference PR Newswire CRANFORD, N.J., April 4, 2024 CRANFORD, N.J., April 4, 2024 /PRNewswire/ -- Citius...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.1402 | -17.9743589744 | 0.78 | 0.95 | 0.62 | 7178198 | 0.72406031 | CS |
4 | -0.0602 | -8.6 | 0.7 | 0.95 | 0.602 | 2447393 | 0.70784511 | CS |
12 | -0.1102 | -14.6933333333 | 0.75 | 1.07 | 0.602 | 1481074 | 0.75334589 | CS |
26 | -0.1412 | -18.0793854033 | 0.781 | 1.07 | 0.6 | 1027646 | 0.74913057 | CS |
52 | -0.4802 | -42.875 | 1.12 | 1.4 | 0.6 | 1060378 | 0.89853861 | CS |
156 | -1.6602 | -72.1826086957 | 2.3 | 4.56 | 0.6 | 1857182 | 1.89540491 | CS |
260 | -0.6402 | -50.015625 | 1.28 | 4.56 | 0.4 | 2285530 | 1.80394721 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions